The surrogate markers(SM) are the important factor for angiogenesis in cancer patients.In Metronomic Chemotherapy (MC) , physicians administer subtoxic doses of chemotherapy (without break) for long periods, to the target tumor angiogenesis. We propose a semiparametric approach, predictive risk modeling and time to control the level of surrogate marker to detect the perfect dose level of MC. It is based on the controlled level of surrogate marker, and the aim is to detect an Optimum Biological Dose (OBD) finding rather than a traditional Maximum Tolerated Dose (MTD) approach. The methods are illustrated with MC trial dataset to determine the best OBD and we investigate the performance of the model through simulation studies.